drugset / Trial / NCT01620268

An Open-Label, Study to Treat Patients With Renal Allograft and Polyoma BK Viruria

NCT01620268

Phase 2 Terminated 24 enrolled Changzheng-Cinkate
RandomizedParallel-groupOpen-labelPrevention

Summary

This study will evaluate the clinical efficacy and safety of a combination of leflunomide and orotic acid in kidney transplant patients with high levels of Polyoma BK viruria for the purpose of preventing Polyoma BK viremia and Nephropathy that could lead to kidney transplant loss from viral damage, acute rejection or both.

Timeline

Start
2012-07
Primary completion
2018-06
Completion
2018-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Leflunomide Small molecule
Subject Orotic acid Small molecule 600 mg

Indications

No indication recorded.